Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02055365 · ClinicalTrials.gov registry record · NA

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

A NA study, sponsored by Rockefeller University.

Completed
Registry status
NA
Development phase
10
Enrollment target

NCT02055365: Completed NA study, sponsored by Rockefeller University.

NCT02055365 is a NA study that has completed, run by Rockefeller University. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02055365, a NA study, has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target

Study Summary

Vaccines have been responsible for preventing millions of deaths and extending the average human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes and associated functions that bring about protective immunity.This study aims to define cellular functions and genes important for the hepatitis B (HBV) vaccine immune response in healthy individuals. The investigators hypothesize that many genes associated with innate and adaptive immune functions are important for an effective HBV vaccine response.

Primary Outcome

Number of differentially expressed genes at time point versus prevaccination baseline (p\<0.05). Following Principal Components Analysis, data from one participant series was identified as a technical outlier and excluded from downstream analyses. Differential gene expression analysis was conducted with the voom/limma tools in the R statistical framework.

Interventions

  • BIOLOGICAL Hepatitis B Vaccine (Recombinant)

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2014-02-18
Est. Completion 2015-01-06
Phase NA
Rockefeller University

117 total trials

What the finished NCT02055365 record still lists

NCT02055365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Hepatitis B Vaccine (Recombinant) is the first listed.

NCT02055365 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02055365 about?

NCT02055365 is a clinical study titled "Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers". Vaccines have been responsible for preventing millions of deaths and extending the average human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes and associated functions that bring about protective immunity.This study aims to define cellular functions and gene...

What is the current status of trial NCT02055365?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2014-02-18. Estimated completion is 2015-01-06.

What interventions are being tested in trial NCT02055365?

The interventions under investigation include: Hepatitis B Vaccine (Recombinant) (BIOLOGICAL).

Who is sponsoring clinical trial NCT02055365?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02055365's enrollment target sits among peer trials

10 1927th of 2000 higher than 26 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02055365, the US trial registry maintained by the National Library of Medicine. NCT02055365 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.